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Abstract (Portuguese) 
A recombinação V(D)J, o rearranjo somático de segmentos génicos variable (V), 
diversity (D) e joining (J), é o fenómeno responsável pela imensa diversidade de reportório 
de receptores de antigénio (ARs) que medeiam o reconhecimento molecular pelo sistema 
imunitário dos vertebrados. Os Recombination-Activating Genes (RAG) 1 e 2 formam a 
endonuclease RAG que reconhece sequências sinalizadoras de reconhecimento (RSSs) 
adjacentes aos segmentos génicos do AR, gerando quebras na dupla cadeia de ADN. A 
junção e reparação destas quebras é realizada pela actividade da maquinaria de reparação 
não homóloga (non-homologous end joining ou NHEJ) em coordenação com a RAG, 
ultimamente gerando ARs funcionais. 
A recombinação V(D)J é regulada a vários níveis. Pensava-se que a expressão de 
RAG estaria restrita a determinados estadios do desenvolvimento linfocitário (células pró/pré 
B e T). A nível molecular, a actividade RAG dá-se pelo reconhecimento direccionado de 
RSSs. Estes apresentam uma estrutura consensus, sendo constituída por um heptâmero, 
um espaçador de 12 ou 23 nucleótidos e um nonâmero, apresentando poucas sequências 
consensus. Estas sequências são portanto consideravelmente degeneradas, favorecendo 
uma panóplia de interacções com a RAG e consequentemente de diversidade de ARs. 
Contudo, existem sequências semelhantes a RSSs, os RSSs crípticos (cRSSs), que se 
presume existirem ao longo do genoma, devido à aleatoriedade da composição nucleotídica 
do mesmo ou simplesmente pela acção de mecanismos evolutivos. Alguns destes cRSSs 
são realmente substratos funcionais da RAG. Devido a tal, a RAG também tem sido 
denominada de “transposase promíscua”. Actualmente, existem três modelos de actividade 
ilegítima de RAG, o modelo de substrate selection error, envolvendo rearranjos entre um 
RSS e um cRSS ou dois cRSSs; o modelo de end-donation, em que os rearranjos são feitos 
entre um RSS e uma quebra de ADN em cadeia dupla independente de RAG; o modelo de 
transposition que ocorre no âmbito de uma reacção legítima em que, por extensão do tempo 
de vida do fragmento excisado, a RAG realiza uma reacção de transposição com reinserção 
do mesmo fragmento. Estes modelos têm como objectivo explicar como a actividade 
ilegítima de RAG pode eventualmente originar assinaturas nucleotídicas, e mutações como 
translocações, que estão na base da instabilidade genómica encontrada em tumores 
linfóides. 
O padrão de expressão de RAG durante a hematopoiese permanece controverso. 
Existem evidências de expressão de RAG em estadios precoces do desenvolvimento 
hematopoiético, anteriormente ao estadio de comprometimento da linhagem linfóide. 
Adicionalmente, a presença de expressão de RAG, bem como de assinaturas nucleotídicas 
reminiscentes de rearranjos, foi descrita em doenças malignas hematopoiéticas quer de 
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fenótipo linfóide como mielóide, nomeadamente em leucemias promielocíticas agudas (APL) 
e leucemias mielóides agudas (AML). Contudo, o papel da RAG na origem, manutenção e 
progressão de instabilidade genómica na transformação hematopoiética permanece 
obscuro. 
Vários repórteres moleculares de actividade RAG têm vindo a ser desenvolvidos, 
com vista a compreender os fenómenos bioquímicos e fisiológicos de actividade RAG. As 
técnicas de quantificação de rearranjos moleculares mediados por RAG têm normalmente 
requerido grandes quantidades de material biológico, bem como procedimentos intrincados 
e morosos. Apesar de algumas limitações terem sido ultrapassadas, e de alguns repórteres 
possuírem um esqueleto retroviral (em vez de extracromossomal), vantajoso por mimetizar 
uma condição mais fisiológica, a detecção de actividade RAG requer ainda passos 
secundários. Até à data, nenhum repórter reuniu um substrato retroviral com um método 
simples e directo de leitura de actividade RAG. 
O nosso laboratório gerou recentemente o GFPi, uma nova ferramenta molecular 
epissomal/retroviral baseada em fluorescência, que permite uma fácil avaliação da 
actividade RAG em vários tipos celulares por permitir o cálculo de um valor de eficiência de 
recombinação (ER) de RAG através da análise de células por citometria de fluxo. 
Como primeiro objectivo deste trabalho, procurámos estabelecer este novo repórter 
optimizando a detecção de actividade RAG no ensaio de recombinação in vitro, através de 
um aumento de expressão dos genes RAG1 e RAG2, localizados nos plasmídios utilizados 
neste ensaio. Concluímos que o referido aumento de expressão permitiu alargar a janela de 
detecção de valores de eficiência de recombinação in vitro.  
Com vista avaliar a sensibilidade do GFPi na detecção de actividade RAG em 
presença de sequências de reconhecimento degeneradas, reproduzimos o setup 
experimental abordado por Kelsoe e colaboradores com o repórter clássico pJH290, desta 
vez com o GFPi. Para tal, variámos a sequência espaçadora de 23 nucleótidos do RSS 
contido no GFPi e submetemos cada repórter a ensaios de recombinação in vitro, de 
maneira a observar a repercussão em valores relativos de actividade RAG. Observámos que 
o GFPi é realmente sensível a variações nucleotídicas nesta estrutura nucleotídica em 
particular, apresentando uma tendência de valores de eficiência de recombinação 
semelhante à literatura, apesar de não ter reproduzido fielmente a mesma. 
Acoplando as vantagens do GFPi à optimização obtida na detecção de valores de 
eficiência de recombinação in vitro, nomeadamente por amplificação ERs até então 
residuais, decidimos testar a aplicabilidade do GFPi na medição de ERs de uma colecção de 
RSSs crípticos (cRSSs) conhecidos por estarem envolvidos no desenvolvimento leucémico. 
Não só validámos esta ferramenta como apta a ser aplicada nestas condições como 
analisámos a funcionalidade destes cRSSs, já descritos na literatura. Ao contrário do que é 
 
                         Screening for RAG activity in haematopoietic tumours using a novel reporter strategy 
x 
mencionado nesta, o GFPi permitiu classificar o cRSS do gene stem cell leukaemia (SCL) 
como possuindo uma actividade RAG detectável, apesar de residual. 
Este novo ensaio permitiu-nos ainda quantificar a eficiência de recombinação RAG 
de um cRSS previamente não detectado, encontrado no primeiro exão do gene phosphatase 
and tensin homologue deleted on chromosome 10 (PTEN), conhecido por estar envolvido na 
origem de leucemias. Provámos que o cRSS do gene PTEN é tão funcional como outros 
RSSs dos loci V(D)J, e que esta actividade RAG se correlaciona com uma mutação 
recentemente encontrada no mesmo local, num paciente oncológico com Leucemia Aguda 
Linfóide de células T. 
Também usufruímos da forma retroviral do GFPi, com vista a quantificar actividade 
RAG endógena em linhas celulares hematopoiéticas tumorais humanas. Para tal, 
desenvolvemos a produção de pseudoretrovirus de GFPi, procedendo à infecção das 
mesmas linhas celulares, quer de origem linfóide como mielóide, de maneira a obter a forma 
integrada do GFPi em número baixo de integrantes por célula. Apesar de termos encontrado 
diferenças em actividade RAG específicas de linhagem (nomeadamente na linha de células 
B Reh que apresentou actividade RAG intensa), não encontrámos nenhum sinal de 
actividade RAG endógena promíscua num curto espaço de tempo, nas linhas celulares 
mielóides.  
Não obstante, descobrimos que o repórter GFPi não só consegue providenciar uma 
medição quantitativa de forma transiente in vitro (na sua forma epissomal), como também o 
faz na sua forma integrada ex vivo (na sua forma retroviral), como substrato estável e mais 
próximo de uma condição fisiológica. 
Assim, concluímos com este trabalho que o repórter GFPi reúne todos os requisitos 
para um repórter de actividade RAG eficiente, acoplado a um método fácil e de leitura 
directa. Como resultado, possuímos agora uma ferramenta robusta adequada a várias 
possíveis aplicações. Prevemos que o GFPi possa possibilitar a descoberta da relação entre 
a actividade promíscua da RAG e o desenvolvimento leucémico, que foi preliminarmente 
abordada neste trabalho, bem como aplicações bioquímicas (na compreensão da fisiologia 
da recombinação V(D)J) e biomédicas (numa perspectiva clínica, como ferramenta de 
diagnóstico). 
Palavras-chave: RAG, recombinação V(D)J, repórter molecular, GFPi, cRSS, 
desenvolvimento leucémico, instabilidade genómica. 
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Abstract (English) 
Recombination-Activating Genes (RAG) 1 and 2, form the site specific recombinase 
that mediates V(D)J recombination at the antigen receptor loci, a process responsible for 
lymphocyte diversity. RAG can also interact with degenerated recognition signal sequences 
(cRSSs) distributed throughout the genome and potentially induce genomic instability. To this 
date, no available reporter of RAG activity has gathered the versatile features of a molecular 
tool with a simple method of readout. Our laboratory has recently generated GFPi, a novel 
episomal/retroviral fluorescence-based molecular tool that allows for fast assessment of RAG 
activity in various cell types. 
 We have found that the GFPi reporter can not only provide in vitro quantitative 
measurement transiently, being sensitive to RSS sequence degeneration, but also ex vivo in 
its integrated form as a stable substrate.  
We have also optimized the in vitro recombination assay (IVRA) for the detection of a 
broader window of RAG activity values. This novel assay allowed us to quantify the efficiency 
of RAG recombination of a selected set of cRSSs, namely a previously undetected cRSS 
found in the first exon of the phosphatase and tensin homologue deleted on chromosome 10 
(PTEN) gene, which is known to be involved in leukemogenesis.  PTEN cRSS was proved to 
be as functional as other V(D)J loci RSSs, and this activity correlates with a novel mutation 
which was recently found in a leukaemic patient in this same site.  
We also made use of the retroviral-based form of GFPi in order to quantify 
endogenous RAG activity in human haematopoietic tumour cell lines of lymphoid and 
myeloid origin. Although we have found lineage-specific differences on RAG activity (namely 
in Reh B-cell line which presented intense RAG activity), we found no signs of promiscuous 
endogenous RAG activity in myeloid cell lines in a short timespan.  
Thus, we believe the GFPi reporter gathers all the requisites for an efficient RAG 
activity reporter, coupled with a fast and direct method of readout. Moreover, we now 
possess a robust tool that is suitable for a number of applications, namely unravelling the 
relation between RAG promiscuous activity and leukaemogenesis, which was preliminary 
addressed in this work. 
 
 
 
Key-words: RAG, V(D)J recombination, molecular reporter, GFPi, cRSS, 
leukaemogenesis, genomic instability. 
 
 
 
                         Screening for RAG activity in haematopoietic tumours using a novel reporter strategy 
xii 
 
 
                         Screening for RAG activity in haematopoietic tumours using a novel reporter strategy 
1 
1. INTRODUCTION 
1.1. Evolution of the Immune System Specificity 
 The generation of immune diversity is nowadays seen as a long story from the 
evolutionary point of view. Ever since pathogens exist, the host’s immune system has 
endured the difficult role of detecting foreign and harmful entities that are extremely diverse, 
ensuring their ablation. Currently two models contain evolutionary explanations regarding the 
host’s solutions for this struggle: a discrimination mechanism, between self and non-self 
entities1 and a danger discrimination mechanism2, with damage signals eliciting immune 
responses. In both cases, the mechanism allowed for an amelioration of the specificity for 
pathogen recognition. This immune specificity was achieved by taking advantage of DNA 
recombination, gene conversion3 and hypermutation of recognition receptors4, generating a 
diverse defence line. However, the innate immune system cannot cope with a great level of 
diversity since the generation of its germline-encoded receptors is limited by genome size5. 
The adaptive immune system, which is to date only described in vertebrates, owes its 
success to the appearance of new cell types, new morphological innovations6, new 
mechanisms of diversity generation and increased specificity for pathogen recognition5. 
Moreover, these specialized cell types enhanced memory strategies, enabling a more 
efficient response to the pathogen’s subsequent attack. The crosstalk within and between the 
innate and the adaptive immune systems was also extremely important in this process7. 
Recombination-Activating genes 1 and 2 (RAG1 and RAG2) had a pivotal role on 
generating the diversity of the adaptive immune system 8-11. They codify for the 
endonuclease or recombinase complex (herein referred as RAG unless individual proteins 
are mentioned) which mediates the recombination of DNA segments, giving rise to unique 
antigen receptors (ARs) present in B and T lymphocytes, a phenomenon named as V(D)J 
recombination11. Due to its “cutting and stitching” properties, RAG allows for a major 
manipulation of the germline information contained in the DNA of lymphocytes11, 12. The RAG 
genes are present in all jawed vertebrates and RAG’s target sequences are highly conserved 
as well (Fig.I, App.5). Despite the existing discussion about the time of appearance of these 
genes, it is thought that RAG evolved from a single transposition event which occurred 
approximately 500 million years ago13. Nevertheless, a RAG-like sequence was also found in 
Echinoderms14 which may provide alternative explanations to RAG’s evolution. 
1.2. V(D)J Recombination  
V(D)J recombination, the somatic rearrangement of variable (V), diversity (D) and 
joining (J) segments, is the phenomenon responsible for the immense diversity of AR 
repertoires that mediate molecular recognition by the vertebrate immune system12. The RAG 
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endonuclease specifically recognizes recombination signal sequences (RSSs) adjacent to 
AR gene segments and generates DNA double strand breaks (DSBs)11, 12. Joining and repair 
of the nicked strands are accomplished by the activity of the non-homologous end-joining 
(NHEJ) machinery, in coordination with RAG, to give rise to functional ARs of B and T cells 
(BCR and TCRs, respectively)15.  
In mammals, the final protein structure originating the AR is a heterodimer: the BCRs 
are composed by an immunoglobulin heavy chain (IgH) which can be coupled either with an 
Igκ or Igλ light chain, whereas the TCRs are either αβ or γδ protein dimmers. Thus, there are 
seven AR loci present in the mammalian genome. 
V(D)J recombination defines several stages of lymphocyte development.  Concerning 
the development of B cells, taking place in the bone marrow, these cells recombine the IgH 
locus (from Pre-Pro to Pro-B stage), rearranging one of the possible light chain loci, Igκ or 
Igλ, (from Pro to Pre-B stage), in order to produce the BCR. If rearranging the Igκ, the cell 
represses the Igλ locus rearrangement: a mechanism known as isotypic exclusion. The cells 
are further subjected to negative and positive selection pressures, avoiding auto-reactivity 
and increasing specificity to a given antigen.  
 Concerning T cell development, αβ-T cells and γδ-T cells arise in the thymus from a 
common progenitor cell originated in the bone marrow16. T cells rearrange the TCRβ, γ, and 
δ loci first at the double-negative (DN) stages (from DN2 to DN3 stage) but there is a strong 
bias for β-chain production. This chain couples to the invariant pre-TCRα chain, forming the 
pre-TCR. The pre-TCR checkpoint occurs from DN3 to DN4 stage enabling survival, 
proliferation and differentiation of these cells. Finally, the TCRα locus is rearranged (from 
DN4 to double-positive, DP, cell stage) and the cell produces the αβ-TCR. It is the TCR that 
allows for the positive-selection stage, where the cell commits either to the CD4 or CD8 
single-positive (SP) lineage, before being subjected to negative selection pressures (which 
eliminate auto-reactive T cells) and exiting the thymus to the peripheral organs. γδ-T cell fate 
is still poorly understood. 
The AR loci vary in number and order of V, D and J segments (also in between 
organisms17) and only the IgH, TCRβ and TCRγ loci bear D segments, which are located 
between the Vs and Js. All segments are flanked by RSSs, which are composed by a 
palindromic seven-nucleotide consensus sequence (heptamer), followed by a 12 or 23-
nucleotide spacer and a nine nucleotide sequence (nonamer) exhibiting few consensus 
positions18, 19 (Fig.1 A). Even though this signature is essential for recombination, these three 
regions can vary in nucleotide composition, allowing for a degenerated permission and 
favouring a wide range of interactions with RAG, consequently affecting the efficiency of the 
rearrangement in course. During recombination, RAG obeys a 12/23 rule, meaning that, with 
few exceptions, it only assembles a 12-RSS with a 23-RSS, allowing for a less promiscuous 
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Figure 1. Schematic representation of V(D)J recombination. A. AR organization B. Snapshots of 
V-J reaction Ba. RAG binding and nicking Bb. Synapsis Bc. Hairpin formation and cleavage Bd. 
Haripin opening and joining.Triangles represent RSSs and rectangles represent AR gene segments. 
In Roth et al., 2003.  
and more targeted activity20. The RSSs’ orientation is also important, since it determines if 
the sequence between the rearranged segments will be inverted or excised21. The usual 
organization of the RSS in the AR loci is such that the rearranged segments (coding 
sequences) remain in the chromosome and the intermediate sequence is excised, along with 
the RSSs (Fig.1 A). 
V(D)J recombination is triggered during lymphocyte development by specific 
environmental conditions. The model nowadays accepted states that RAG targets and binds 
the RSSs20 (likely binding the 12-RSS before the 23-RSS22), nicking one of the DNA strands 
precisely at the joint between the coding sequence and the RSS heptamer, exposing a 3’ 
hydroxyl group19 (Fig.1 Ba). The nicking is followed by the pairing of the recruited RSSs, with 
the help of RAG, forming the synapsis19 (Fig.1 Bb). The DSB occurs due to a nucleophilic 
attack of the nicked strand, which invades the 5’-phosphorylated signal-end of the other (in a 
transesterification reaction, similarly to a transposition mechanism) forming a hairpin 
structure19 (Fig.1 Bc), resulting in the excision of the fragment in between the coding 
sequences (RSSs included). The hairpins formed at both coding sequences, together with 
RAG and the blunt signal ends, form the post-cleavage complex23. The ubiquitous Non-
homologous end joining (NHEJ) repair machinery is then recruited, resolves this structure 
and forms the coding joint by nicking the hairpins in a non-targeted manner (a process 
undertaken by the protein Artemis24) and connecting them to each other19 (Fig.1 Bd), 
allowing for the loss or addition of 
nucleotides (in the last case provided 
by Deoxynucleotidyl Transferase, 
TdT) in the joining25. The signal joint 
is composed by the excised fragment 
connected through the RSSs, forming 
an excision circle which will be lost 
during cell division. Alternatively, 
when the signal end is joined to the 
coding end of the other signal, rather 
than forming a signal joint, forms a 
hybrid joint, resulting in an 
unproductive recombination. The 
same may happen when the same 
pairs of coding and signal joints are 
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rejoined, forming an open-and-shut joint26.   
Due to the combinatorial properties of the V(D)J segment assembly (which can 
generate 107 possible ARs27), the randomness of Artemis and TdT activity, pairing of the AR 
heterodimers and to somatic hypermutation (in B cells) the diversity provided for AR 
generation is approximately 1010 possible ARs in B cells and 1017 in T cells28.  
1.2.1. Regulation of V(D)J Recombination 
 V(D)J recombination is regulated at several levels.  Lineage and developmental-stage 
restrictions of V(D)J recombination are controlled by RAG expression (which occurs in two 
waves of expression during lymphocyte development, mentioned in 1.2.) and by RAG’s 
differential accessibility to the loci29. Despite the little information on this mechanism, it is 
known that locus accessibility is controlled by large-scale chromosome dynamics30, specific 
histone methylation profiles31, secondary chromatin structures, chromatin remodelers32, cis-
acting elements33-35, transcriptional factors36 and RSS nucleotide composition itself37. All of 
these factors dictate the chromosome region and the AR locus to be exposed to RAG, the 
segments to be recruited for rearrangement38, the order of AR and segment rearrangement39, 
and some of them even regulate localized RAG deposition36. Concerning the cell cycle 
regulation, V(D)J recombination is restricted to the G0/G1 stage, which is when RAG is 
expressed. The extracellular environment also conditions V(D)J recombination since it 
influences RAG and repair machinery components’ accumulation and degradation in the cell 
(eg. Fig.II, App.,30, 40). Besides serving as an intermediate for V(D)J recombination, RAG 
also plays a regulatory role in several stages of V(D)J recombination, namely in the hairpin 
opening stage, in stabilization of the post-cleavage complex and in the recruitment of the 
NHEJ machinery. 
Allelic exclusion is also a regulatory mechanism inherent to V(D)J recombination, 
namely to all B cell and some T cell AR loci15. It guarantees the expression of a single BCR 
in the cell, by silencing the allele which is not being rearranged at the AR locus, through a 
feedback inhibition mechanism. If the rearrangement is unproductive, then this restriction is 
withdrawn and the other allele is rearranged. Recently, new data provided evidence that 
RAG is implicated in the regulation of allelic exclusion41. 
 Additionally, V(D)J recombination does not require but is enhanced in vitro by the 
presence of the high mobility group proteins 1 and 2 (HMGB1 and 2)42, which suggests that 
these proteins may regulate V(D)J recombination in vivo.  
 Due to this complex orchestrated sequence of events, a model of V(D)J 
recombination was recently published, hypothesizing that all of these regulatory features 
(chromatin remodelling complexes, RAG, transcription factors and repair machinery) were 
localized in a single sub-nuclear compartment known as a “V(D)J factory”, having RAG as a 
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nucleating agent30. This nuclear configuration would facilitate the alterations of the 
chromosome architecture, allelic pairing, V(D)J segment sub-nuclear repositioning, 12/23 
long-range RSS assembly, all due to a more efficient coupling of events and a more 
regulated environment. 
1.3. RAG  
The organization of the RAG locus is not common, since both genes are located 
close to each other (separated by approximately 8kb), contain single large coding exons, and 
are convergently transcribed. This organization, as well as RAG’s ability to potentially induce 
a transposition-like reaction during V(D)J recombination, was the starting point for RAG’s 
evolutionary hypothesis as having been originated from a transposition event43 (mentioned in 
1.1.). 
The murine RAG proteins have 1040 (RAG1) and 527 (RAG2) residues each. Core 
RAG1 bears the binding domains required for activity: a heptamer and a nonamer binding 
domain (recently confirmed by crystal structure to bind the nonamer44) which bind the RSS, 
and a RAG2 binding site. Interestingly, the Zn ions found to bind core RAG-1 are determinant 
for RAG-cleavage activity45. Although it is not known if RAG2 has additional RSS binding 
sites (since some RAG-2 mutants impair DNA binding46), it is accepted that, as RAG1, RAG2 
holds domains that induce DNA cleavage and hairpin formation46, 47.  
Paradoxically, RAG1 was demonstrated to be more promiscuous than previously 
thought, since it may bind non-RSS sequences. This effect is masked by the RAG2 protein, 
which was recently proved to avoid RAG1 mistargeting of RSS binding48. RAG2 was also 
described as playing a role at enhancing RSS recognition, increasing RAG1 affinity for DNA 
by 20-fold49. The non-core RAG domain functions lie mainly on the C-terminal portion of 
RAG250. This region suppresses RAG-induced transposition51 (mentioned in 1.3.2.), restricts 
V(D)J recombination to the G0/G1 cell cycle stage and contains a PHD motif which 
recognizes H3 methylated histone (found in the V(D)J segments in enriched amounts at 
specific residues)31. Overall, RAG1 is currently seen has having the primary specific binding 
and cleavage activities, with RAG2 and HMGB1/2 functioning as its cofactors.  
1.3.1. Regulation of RAG expression 
As previously referred in 1.2.1., regulation of RAG expression directly influences 
V(D)J recombination. The controlling mechanisms underlying RAG expression fluctuations 
during lymphocyte development are still not well understood. The regulation of the RAG 
locus by cis-acting elements and transcription factors in a lineage-specific manner52-54 does 
not fully explain this phenomenon. However, greater attention has been given to other 
regulatory mechanisms such as cell cycle signalling, which regulates RAG degradation at the 
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protein level55 and AR signalling53, 56 which, in turn, regulates RAG transcription levels. 
Additionally, it was thought that the RAG locus was controlled in a similar way to the AR loci, 
i.e. that it was meant to be closed unless an instructive environmental signal induced 
chromatin opening (such as cis-acting elements or transcription factors). Nevertheless, it was 
not until recently that a new finding provided the hint that the locus is exposed: NWC, a third 
evolutionarily conserved gene located within the RAG locus, was found to be ubiquitously 
expressed and controlled by the intragenic RAG2 promoter. Moreover, the exception was 
observed in immature and B/T mature lymphocytes in which its expression was driven by the 
RAG1 promoter, transcribed as a RAG1-NWC hybrid mRNA, therefore possibly representing 
a natural antisense transcript for RAG2 and consequently regulating RAG expression in a 
lineage-restricted and time-dependent manner57 
It is also thought that receptor editing requires regulation of the RAG locus in 
immature B lymphocytes; although it is an unresolved issue, some claim mature B 
lymphocytes re-acquire RAG expression and undergo receptor editing too.  
RAG expression pattern during haematopoiesis remains controversial. There is 
evidence showing that RAG is expressed at earlier stages of haematopoietic development, 
prior to lymphoid commitment58. Furthermore, occasional V(D)J rearrangements have been 
observed in dendritic cells59, 60, suggesting that RAG activity it is not restricted to the 
lymphoid haematopoietic compartment. 
1.3.2. RAG and genomic instability 
 The genomic instability elicited by RAG during V(D)J recombination can be seen as 
the counterpart of the immune system’s physiology. However, that counterpart is 
astonishingly probable: taking place on a daily basis, RAG induces loads of targeted DSBs 
waiting to be repaired in an adequate manner within the lymphocyte population. Due to this 
demanding task of accurately remodelling the genome, V(D)J recombination has been seen 
as “a disaster waiting to happen”61. Oddly, RAG-mediated genomic instability events seem to 
rarely trigger oncogenesis in a lifetime. It is thought that the cell’s protective regulatory 
properties and their influence on cell proliferation may be the reason 19.  
Sequences similar to RSSs, cryptic RSSs (cRSSs), are predicted to exist throughout 
the genome62, originated by chance or due to evolutionary mechanisms63. They usually bear 
conserved heptamer and nonamer motifs, which flank a 12- or 23-spacer-like sequence.  
Although some nucleotide positions are more required than others, all of these regions may 
vary in nucleotide composition. In the human genome, the predicted number of cRSSs is 
controversial: Lewis et al. prediction reaches 10 million62 whereas the in silico prediction from 
Cowel et al. states it is ten-fold less63. Some of these cRSSs are functional substrates for 
RAG. Therefore, RAG has also been named “promiscuous transposase”19. Currently, three 
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Figure 2. Models of RAG illegitimate activity. A. Substrate selection error model; B. End-donation 
model; C. Transposition model. Triangles represent RSSs, blue rectangles represent AR gene 
segments and red rectangles represent an oncogene. In Roth et al. 2003 
models of RAG’s illegitimate activity have been proposed19: the substrate selection error 
model (Fig.2 A), involving rearrangements between a RSS and a cRSS or two cRSSs; the 
end-donation model (Fig.2 B), in which the rearrangements involve a RSS and a DSB with a 
RAG-independent origin; the transposition model10 (Fig.2 C), which occurs in the frame of a 
legitimate reaction, in which by extending the half-life of the excised fragments, RAG drives a 
transposition reaction and fragment reinsertion. In all three types of events, the resulting 
configuration of the DNA sequence serves as a rearrangement signature of the event that 
took place. These signatures turned out to be extremely useful when studying RAG activity 
outside the lymphoid compartment and/or its improper activity in pathological conditions (as 
being associated to oncogenesis). All of these three phenomena may trigger oncogenesis in 
several ways (for example, bringing an oncogene in proximity to a strong promoter or 
enhancer, truncating a tumour suppressor protein or shifting the DNA sequence of a tumour 
suppressor gene out of frame). 
Haematopoietic malignancies display a very high incidence of chromosomal 
aberrations and the mechanisms underlying this genomic instability are still under intense 
scrutiny. Regarding lymphoid leukaemias, it has been shown that, in some  T-cell Acute 
Lymphoblastic Leukaemias (T-ALL), RAG expression persists and is found in T cell 
maturation stages normally devoided of RAG activity64.  
Some cRSS were found to be recruited for translocation events, leading to 
leukaemogenesis. Following the substrate selection error model, cRSSs near 
oncogenes/tumour suppressors have been described to be recruited for translocations 
involving one of the AR loci: the t(11;14)(q13;q32) translocation of the cyclin D1 gene and 
IgH leading to mantle cell lymphoma65; the t(9;14)(p13;q32) translocation of Pax5 and the 
IgH locus leading to lymphoplasmacytic lymphomas66; the t(11;14)(p13;q11) translocation of 
Lmo2 and TCRδ locus67, the t(1;14)(p34;q11) translocation of TAL-1 (or SCL) and TCRδ 
locus68 and the t(7;9)(q34;q32) translocation of TAL-2 and TCRβ locus68, all leading to T-
ALL. cRSSs can also 
be recruited along 
with other cRSSs: 
that is the case of the 
1p32 SCL/SIL 
mutation, which is 
the most frequent 
genetic event leading 
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Figure 3. Representation of a number of existing RAG activity reporters. (not to scale) ampR – 
ampicillin resistance gene; P-promoter; STOP – STOP codon; CAT- chloramphenicol acetyl 
transferase; LTR – long terminal repeat; Vk, Jk – coding segments of the Igk locus; neoR – neomycin 
resistance gene; gpt – guanine-xantine phosphoribosyl transferase gene; lacZ – β-galactosidase 
gene; VEX – GFP-variant gene; EGFP – GFP-variant gene; open and closed triangles represent 12- 
and 23-RSSs, respectively. 
to T-ALL, in which a 100kb is deleted69.  
RAG expression and rearrangement signatures have been described in 
haematopoietic malignancies with a myeloid phenotype, such as Acute Promyelocytic 
Leukaemia (APL)70 and Acute Myeloid Leukaemia (AML)71, 72. Little is known about RAG’s 
influence in solid tumourigenesis. However, an isoform of the EGF receptor (EGFRvIII) is 
generated in the brain through internal deletion mutations on specific exons. Since the gene 
is flanked by cRSSs it was suggested to be rearranged by a RAG-mediated event, leading to 
gliomas73. 
1.3.3. Quantification of RAG activity 
Several molecular reporters have been developed in order to understand the 
biochemical21 and physiological74 features of RAG activity (Fig.3). Extrachromosomal 
classical reporters, such as pJH290 served as molecular tools for RAG activity 
standardization measurements (Fig.3 A, 21, 75). The assessment of RAG efficiency of 
recombination was very laborious and time-consuming since it required cell transfection, cell 
lysis, fragment digestion and purification for further transformation into bacteria. The final 
readout of the number of recombined molecules was provided either through the ratio of 
different antibiotic-resistant colonies or through PCR profiles. Moreover, the in vitro assays 
involved high amounts of biological material and intricate multi-step procedures21. This 
caveat has been later tackled through the use of integrated recombination substrates76 (built 
onto a retroviral 
backbone, Fig.3 
B, C). Retroviral 
strategies are 
critical as they 
enable the 
targeting of poorly 
transfectable cells 
and the delivery 
of a stable 
integrated, more 
physiologic 
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reporter substrate. Although the in vitro assay’s readout system has been improved over the 
years, through the use of reporters bearing genes that codify for fluorescent proteins 
detectable by flow cytometry (Fig.3 D, E,77), the detection still requires secondary steps76, 77, 
such as enzymatic reactions or antibody stainings.  
Through the use of these valuable molecular tools, quantification of RAG activity has 
been the vehicle for studying the influence of RSS sequence composition on RAG interaction  
not only with the V(D)J loci, dictating the diversity of the AR repertoire78, but also with the 
whole genome, where cRSSs exist and appear to participate in tumourigenesis19. The RSS 
degeneracy allows for a not so nucleotide-restricted action of RAG: even some V(D)J loci 
RSSs exhibit variations in the most conserved nucleotide positions (for example in the 
nonamer or heptamer). Moreover, the synergistic effects of different nucleotide positions 
spread throughout the RSS are not completely understood, which may also be an influencing 
factor on RAG’s activity. 
 The first approach to RSS analysis was made by using a linear nucleotide 
comparison, i.e., the variation of single nucleotides at each position to find their individual 
importance. Simultaneously, the concept of consensus RSS (herein referred as “Cons”) 
appeared as the sequence that better depicts the average physiological efficiency of 
recombination of the RSSs found in the AR loci59.  Recently, Kelsoe’s laboratory classified 
RSSs according to an algorithm that accounts for the RSS’ nucleotide relative positional 
information and estimates its probability of occurrence in the population of mouse RSSs. By 
examining the nucleotide relationships within a given DNA sequence, the algorithm produces 
a RSS information content (the RIC score79) which is the sequence’s theoretical 
recombination potential. The criterion of functionality for 12-RSS was established to be ≥-40, 
whereas for 23-RSS it was ≥-60. This in silico method defined a different consensus RSS 
(herein referred as “ConK”) as the most conserved 23-spacer (which does not exist in 
nature), as well as an ideal 23-spacer (“spaMI”) defined as having the most frequent 
nucleotide correlations and differing at five nucleotide positions from ConK (one single and 
two doublet mutations, named as “(MI)G4”, “(MI)G14/15” and “(MI)C19/20”, respectively)78. 
spaMI was later found to exist in V(D)J loci mouse RSSs (near gene and pseudogene VH 
segments at the IgH locus). spaMI was not associated with consensus heptamer and 
nonamer but with a low-efficiency non-consensus nonamer, composed of a 5’CAG motif 
(“CAGnon”). The authors progressed to dissect the contribution of different 23-RSS spacers 
to the recombination reaction78, by determining the in vitro efficiency of recombination 
associated with this set of spacers and respective point-mutated sequences in the context of 
a consensus heptamer and nonamer (Table I, App.), using a slightly modified version of the 
classical pJH290 excision reporter system (Fig.3 A, 75), the p290T, and a modified in vitro 
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Figure 4. The GFPi reporter. A. Linear representation of the MSCV-IRES-mRFP retroviral region 
(not to scale); B. MSCV-GFPi-IRES-mRFP structure (not to scale); C. The resulting GFPi structure in 
the presence of RAG activity D. GFPi in vitro recombination assay was performed in the presence 
(R1/R2) or absence (mock) of RAG activity: Left, GFP/RFP flow cytometry dot plot analysis of 293T 
cells (representative experiment); right, bar graph with the average ER (n=8, t-test P value < 0.0001). 
recombination assay (IVRA), by electroporation of murine pre-B cells which bear 
endogenous RAG activity. 
1.3.3.1. The GFPi reporter 
 Our laboratory has generated a RAG activity reporter based on the murine stem cell-
retroviral backbone, the MSCV vector80. The MSCV-mRFP version (L. M. Sarmento, 
unpublished) was generated by replacement of the Green Fluorescence Protein (GFP) in 
MSCV-GFP80 by the monomeric Red Fluorescence Protein (mRFP1) gene81. The MSCV 
contains two long terminal repeats – LTRs – placed at both ends; the 5’LTR contains the viral 
promoter and is followed by a restriction multiple cloning site (MCS). Next, an internal 
ribosomal entry site (IRES) followed by the mRFP gene enables the direct detection of 
transfected or retroviral-infected cells, as mRFP positive, allowing for the expression of the 
bicistronic transcript encompassing the coding sequence cloned in the MCS, along with the 
mRFP marker (Fig.4 A).  
The RAG reporter structure was cloned into the MCS of the MSCV-mRFP (Fig.4 B). It 
comprises an inverted GFP sequence, flanked by two RSSs, a 12- and a 23-spacer RSS, 
positioned, respectively, at the 5’ and 3’ ends of the inverted GFP. The RSSs are both 
oriented 5’ to 3’ (heptamer to nonamer orientation) and their nucleotide composition was 
defined according to the consensus sequences (Cons) used in the classical pJH290 
reporter21. Therefore, this particular plasmid was named “GFPi-Cons”. The structural relation 
between the RSSs and their orientation determines that their recognition will lead to an 
inversion instead of an excision reaction18. The delivery of this reporter into cells will first 
render them mRFP positive. The presence of RAG activity will result in the inversion of the 
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GFP coding sequence and the acquisition of the GFP fluorescence (Fig.4 C). This reporter 
construct can be used as an extrachromosomal substrate, in an in vitro recombination assay 
(IVRA), by direct transfection, or used to produce retroviral particles to infect primary cells 
and measure RAG activity in vivo.  
Preliminary experiments have confirmed the functionality of the GFPi reporter. The 
GFPi reporter was used to measure RAG activity in an IVRA adapted from Hesse et al21. As 
shown in Fig.4 D, in the absence of RAG, expression of GFP was not detected in the mRFP 
positive population, whereas in the presence of RAG1 and RAG2, an average of 1,94% (and 
a standard deviation of 0,43) mRFP positive cells were GFP positive. The efficiency of RAG 
activity was defined as “efficiency of recombination” or “ER”, corresponding to the frequency 
of GFP positive cells detected in the mRFP positive population. 
2. AIMS OF THE PROJECT 
In spite of the breakthrough of applying molecular reporters to study V(D)J 
recombination and RAG-mediated genomic instability, so far, no reporter has gathered the 
retroviral reporter structure with a direct and simple method of readout. In this work, we 
aimed at establishing a novel retroviral-fluorescent reporter of RAG activity by optimizing the 
detection of RAG activity (4.1.) and proving the reporter’s sensitivity to RSS sequence 
degeneration (4.2.). With this new tool, we aimed at assessing the functionality of a set of 
cRSSs known to be involved in leukaemogenesis (4.3., 4.4.) and characterize, qualitatively 
and quantitatively, the presence of endogenous RAG activity in human leukaemic tumour cell 
lines (4.5.). 
3. MATERIALS AND METHODS 
3.1. Cell culture 
HEK (human embryonic kidney fibroblasts) 293T cells (4.1., 4.2., 4.3. and 4.4.) and 
3T3 fibroblasts (4.5.) were cultured in DMEM82 media (GIBCO) supplemented with Fetal Calf 
Serum 10%, Sodium Pyruvate 1%, L-Glutamine 1%, PenStrep 1% (Invitrogen), at a 
temperature of 37ºC and 5% CO2 conditions. The cells were harvested, washed and re-
seeded at low density every two to three days. 
HL-60 ,SUPT1, Nalm6, Jurkat, Reh and K562 tumour cell lines (4.5.) were cultured in 
RPMI Glutamax media (GIBCO) supplemented with Fetal Calf Serum 10%, Sodium Pyruvate 
1%, PenStrep 1% , at a temperature of 37ºC and 5% CO2 conditions. The cells were 
maintained at a concentration of 0,25 x 106 cells/mL. As so, cells were washed and re-
seeded every two to three days and purged from dead cells by Ficoll (Pharmacia) gradient 
when necessary. 
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3.2. In Vitro Recombination Assay (IVRA) 
The IVRA protocol was adapted from Hesse et al21. Briefly, in 4.1., 4.2., 4.3. and 4.4., 
0,5 x 106 HEK 293T cells were seeded in a 6-well plate well in 2,5 mL of media. After 24 
hours, cells were co-transfected by replacing 600 L of media by a transfection mix 
containing 10 μL of Lipofectamine2000 (Invitrogen), 600μL of Optimem and a total of 10μg of 
pDNA: with 10μg of mock plasmid DNA or with 5μg of GFPi (or a GFPi-derived plasmid) and 
5 g of mock plasmid (negative control) or 2,5μg of H2K-RAG1 plus 2,5μg of H2K-RAG2 
(H2k assay) or 1,6g of pCMV-RAG1 plus 1,4g of pCMV-RAG2 plus 2g of mock plasmid 
(equimolar CMV assay). After 16 hours of incubation (over-night) in transfection mix-
containing media, cultures were washed with fresh media. The cells were further cultured for 
48 hours, harvested, and analysed by flow cytometry for GFP and mRFP fluorescence 
detection at the single cell level. Variations to the protocol are indicated in figure legends or 
results. 
3.3. Statistical analyses 
In 4.1., 4.2. 4.3. and 4.4., to every type of IVRA, an average and a standard deviation 
of ER were determined for each independent experiment, by pooling the replicates. When 
pooling experiments, the background average value was subtracted [corresponding to the (-) 
GFPi negative control] and the standard deviation was found by the formula SDfinal = 
. When comparing groups of 
data, a non-parametric t-test was applied using the GraphPrism software. Whenever 
necessary, a Welch correction added. 
3.4. Flow cytometry analyses 
In 4.1., 4.2., 4.3., 4.4. and 4.5., flow cytometry data were acquired in MoFlo (RFP was 
measured on channel 7 (FL7) with a Krypton Crystal Laser CL-2000 Dioded 561nm Yellow 
Laser and a filter pass D630/75; GFP was measured on channel 1 (FL1) with an Argon 
Sapphire-200mV 488nm Blue Laser, with D530/40 filter pass). Data was further analysed 
using the Flowjo software. In 4.5., flow cytometry data were also aquired in FACS Calibur in 
order to calculate viral titers, respectively (GFP was measured on channel 1 (FL1) with a 
15mW SPECTRA-PHYSICS Aircooled 488nm laser). Data was further analysed using the 
CellQuest software. 
3.5. Immunoblot analysis 
In 4.1., HEK 293T cells were transfected with equimolar amounts of H2K-RAG1 or 
CMV-RAG1 or H2K-RAG2 or CMV-RAG2, cultured for 36 hours, after which the cells were 
lysed and protein extracts run in a SDS-PAGE. Separated proteins were transferred onto a 
nitrocellulose membrane, and probed with antibodies anti-RAG1 (rabbit polyclonal diluted 
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1:100 or 1:500, K-20 SantaCruz) or anti-RAG2 (rabbit polyclonal diluted 1:50 or 1:500, M-300 
SantaCruz) antibodies followed by the secondary anti-rabbit-HRP antibody (Thermo 
Scientific) probing. For the internal controls, the primary antibodies used were anti-α-tubulin 
(mouse monoclonal, diluted 1:500 or 1:1000, SIGMA) and anti-β-actin (goat polyclonal, 
diluted 1:1000 or 1:2000, C-19 SantaCruz) and the secondary were anti-mouse-HRP 
(Thermo Scientific) and anti-goat-HRP (Pierce), respectively. Immunoblot washes and 
incubations were performed in Tris-Buffer-Saline supplemented with 0.1% Tween-20. 
Detection was performed using the Thermo Scientific Pierce Fast Western Blot Kit and ECL 
Substrate chemioluminescent kit (Thermo Fisher). Prior to re-probing, membranes were 
subjected to a stripping solution of 0,0625M Tris-HCl pH6.8, 2% SDS, 1/100 (v/v) -
mercaptoethanol and incubated at 56ºC for one hour. 
3.6. Molecular cloning 
3.6.1. CMV-RAG Cloning 
In 4.1. CMV-RAG1 was obtained by excising a 4.7Kb fragment from a Bluescript pKS-
RAG1 plasmid (L. Sarmento), comprising the RAG2 5’ mini-exon and the RAG1 coding 
sequence, through the use of XhoI/NotI restriction enzymes (NEB). This fragment was further 
ligated to a previously processed 3.6Kb pCMVβ vector (Invitrogen) cut by NotI and XhoI 
(NEB). Likewise, CMV-RAG2 was obtained by excising a 2.4Kb fragment containing RAG2 5’ 
mini-exon and RAG2 coding sequence with SalI/AseI (NEB) restriction enzymes. As the AseI 
site disrupted the TAA stop codon contained in the 3’ region of RAG2 coding sequence, the 
AseI end was filled-in with Klenow (NEB) prior to SalI digestion. Likewise, the 3.6Kb recipient 
vector pCMVβ was also cut by NotI followed by fill-in with Klenow and further digestion with 
XhoI resulting in a XhoI/NotI(Klenow)-ended fragment allowing for TAG stop codon 
reconstitution upon ligation with the RAG2 fragment. 
CMV-RAG1 was obtained by excising a 4.7Kb fragment from an intermediate 
Bluescript pKS plasmid, used in the above H2k-RAG1 cloning, comprising RAG1 5’ mini-
exon and RAG1 coding sequence, through the use of XhoI/NotI restriction enzymes (NEB). 
This fragment was further ligated to a previously processed 3.6Kb pCMVβ vector (Invitrogen) 
cut by EcorV (NEB) followed by NotI and XhoI, generating CMV-RAG1. Likewise, CMV-
RAG2 was obtained by excising a 2.4Kb fragment containing RAG2 5’ mini-exon and RAG2 
coding sequence with SalI/AseI (NEB) restriction enzymes. As the AseI site disrupted the 
TAA stop codon contained in the 3’ region of RAG2 coding sequence, this fragment was 
further processed by Klenow (NEB), as well as the 3.6Kb recipient vector pCMVβ, which was 
also cut by NotI, processed by Klenow and further cut by XhoI resulting in a 
XhoI/NotI(Klenow)-ended fragment allowing for TAG stop codon reconstitution and 
generating CMV-RAG2. 
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3.6.2. GFPi-Cons Cloning 
In 4.1., The GFPi-Cons reporter was generated by PCR with the use of specific 
primers, a plasmid containing the GFP gene as a template (MSCV-GFP) and Pfu polymerase 
(Promega). The core of this strategy relied on the PCR primers’ design. As an example, an 
expected sequence of the GFPi-Cons PCR product is depicted in Fig.III and the respective 
primers used in Table I, both in Appendix I (App.).  
Left to right (5’ to 3’), this sequence displays a XhoI restriction site, a 5’ to 3’ 
consensus 12-RSS, the reverse complementary sequence of a Kozak-GFP fusion, a 5’ to 3’ 
consensus 23-RSS and a SmaI site. The regions used for primers’ design are underlined and 
at least 20 nucleotides for GFP hybridization were included. 
The fragment was further submitted to a Taq polymerase (Invitrogen) poly(A)-tail 
extension in order to allow for their ligation to the intermediate vector pGEM-Teasy 
(Promega). This vector was further amplified in Escherichia coli, and the selected clones 
were used to extract the final XhoI/SmaI fragments to be ligated to the MSCV-mRFP vector 
previously digested with XhoI and HpaI, generating GFPi-Cons (Sarmento, unpublished). 
The final vector was sequenced for fragment confirmation at the IGC Sequencing Facility. 
3.6.3. GFPi-23-RSS reporters Cloning 
In 4.2., GFPi-ConK, GFPi-spaMI, GFPi-(MI)G4, GFPi-(MI)G14/15, GFPi-(MI)C19/20 
and GFPi-spaMI-CAGnon fragments were cloned using the exact same methodology as in 
3.6.2., with the exception of the reverse primer oligonucleotide used for each 23-RSS 
reporter cloning. The 12-RSS forward primer was used in all PCR reactions and its sequence 
is an exact match of that underlined in Fig. III (App.). Table I (App.) lists the 23-RSS 
sequences contained on each GFPi-reporter and the respectively designed reverse primers.  
3.6.4. GFPi-cRSS reporters Cloning 
In 4.3. and 4.4., GFPi-VH, GFPi-Jβ, GFPi-Lmo2, GFPi-SCL and GFPi-PTEN reporter 
versions were originated using the exact same methodology as in 3.6.2., with the exception 
of the reverse primer oligonucleotide used for each 12-RSS reporter cloning. Table II (App.) 
lists the 12-RSS and cRSS sequences used in this work, as well as their respective primer 
sequences. 
3.7. Viral production and titers 
In 4.5., the viral production was adapted by Naldini et al. Briefly, 2 x 106 HEK 293T 
cells were seeded on a pre-coated Poly-L-Lysine (SIGMA) 20cm2 6cm-diameter dish in 5 mL 
of media and incubated for 24 hours. For viral production, cells were co-transfected for 
16hours in 4 mL of media using the calcium phosphate method with 5g of pKAT retroviral 
packaging vector, 5g of pCMV-VSV-G envelope glycoprotein encoding plasmid and 10g of 
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MSCV-GFPinv in a 1 mL transfection mix containing 0.165M CaCl2 in Hydrogen-Phosphate-
Buffer-Saline (HBS with 0.75mM Na2HPO4, 140mM NaCl, 5mM KCl and 6mM Dextrose). 
Transfections were concluded by replacing the transfection media by 3mL of fresh media 
supplemented with HEPES 20mM for viral harvesting. Virus-containing media were collected, 
filtered with 0,45 filters at 24, 48 and 72h post-transfection conclusion. 
Viral titers were estimated by using virus volumes (V.Vol) of 100μL or 200μL of 24, 48 
or 72h stocks to infect 1x105 3T3 fibroblasts (pre-seeded 24 hours prior at 0,5x105/condition) 
in the presence of 8g/mL of Polybrene (Hexadimethrine bromide, SIGMA) by spin-infection 
at 2500 rpm, 30 min., RT. Frequencies of infection (FI) were determined by measuring the 
cells positive for the IRES-coupled fluorescence by flow cytometry 4 to 5 days after infection. 
The viral titer (VT) was calculated with FIs equal or lower than 0,5 since the n. of infectious 
particles (IP) is directly proportional to the number of cells (NC) when Multiplicity Of Infection 
(MOI) is equal or lower than 1 and considering that a retroviral infection carried out with a 
MOI of 1, i.e n. infectious particles (IP) = n. cells (NC), gives rise to a FI of 0,5. Therefore VT 
(IP /mL) = [FI x NC x (1/V.Vol)] /0,5 . The viral titers obtained were 1-2x106 IP /mL. 
3.8. Cell line infections 
In 4.5., 1 x 105 cells of HL-60, K-562, SUPT1, Jurkat, NALM-6 and Reh tumour cell 
lines were infected on a previously retronectin-coated (5μg/cm2, TaKara) 2cm2 well-plate. 
Viral suspensions of MSCV-mRFP or MSCV-GFPi were added at a MOI 5:1 and the cells 
were centrifuged for 2,5h at 2500rmp RT. Polybrene (Hexadimethrine bromide, SIGMA) was 
added in a concentration of 4μg/mL in order to facilitate viral adhesion. 24 hours later, the 
cells were submitted to a second round of infection in the exact same conditions. 
4. RESULTS 
4.1. Optimization of the GFPi IVRA 
The efficiency of RAG activity detected in the preliminary GFPi in vitro experiment 
(ER = 1,94% ± 0,43) is lower than that described when using other reporters bearing the 
same consensus RSSs63. This could be either due to the presence of inhibitory nucleotide 
sequences flanking the reporter cassette (in the MSCV-mRFP vector) and/or to suboptimal 
levels of RAG expression when using the Major-Histocompatibility-Class I (MHC-I) promoter, 
named H2K, present in the RAG expression plasmids used (H2k-RAG). To address this 
issue, we subcloned RAG1 and RAG2 coding sequences under the control of the CMV 
promoter to test the ER of GFPi-Cons by IVRA in a context of RAG overexpression. Firstly, 
H2k and CMV-driven RAG protein levels were compared by immunoblot analysis of 293T 
cells transfected with equimolar amounts of H2k-RAG1 or CMV-RAG1 (Fig.IV A and B, 
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Figure 5. Representative flow cytometry analysis of control (-) GFPi-Cons (left), H2k-RAG 
GFPi IVRA (middle) and CMV-RAG GFPi IVRA (right). Events were gated on RFP+ (x axis) and 
GFP+ (y axis); the frequency of double-positive events (ER) average and standard deviation is 
highlighted in bold; n=3 replicates of one independent experiment. 
App.), or H2k-RAG2 or CMV-RAG2 (Fig.IV C and D, App.). Since we have found a 
remarkable difference between H2k-RAG and CMV-RAG protein levels, we optimized the 
detection in order to better determine such different levels. CMV-RAG1 and RAG2 were 
successfully detected when titrating cell extracts to half, 1/5 and 1/10 of their original 
concentrations and using standard antibody concentrations (Fig.IV A and C, App.). 
Conversely, H2k-RAG1 and RAG2 were detected by doubling the amount of loaded cell 
extracts and using a higher antibody concentration, allowing for a comparison between H2K 
and CMV-driven expression (Fig.IV B and D, App.). Overall, this analysis indicates that 
CMV-driven expression 
of RAG gives rise to at 
least 10 to 20-fold more 
protein than the H2k 
promoter. 
Subsequently, CMV-RAG1 and CMV-RAG2 were used in an IVRA, along with the 
GFPi-Cons reporter, in equimolar amounts to H2k-RAG (Fig.5). CMV-RAG exhibited a 20-
fold higher ER than H2k-RAG (60,85 ± 1,75 vs. 3,01% ± 1,01; n=9). This efficiency greatly 
exceeds the average of 4-6% described in the literature when using pJH29063, 78, which 
measures the number of recombined substrate molecules. Detailed analysis of 
recombination in the RFP+ population, bearing the maximum number of reporters per cell and 
which display maximum efficiency of recombination (MIFRFP=150), shows that CMV-RAG 
expression, when compared to H2k-RAG, not only generates 10-fold higher frequency of 
GFP+ cells (95,92 ± 0,39 vs 8,49 ± 2,22) but also 10-fold higher number of recombined 
substrates in average per cell, represented by the value of the mean intensity of GFP 
fluorescence (MIFGFP, 1145,12 ± 120,52 vs 88,75 ± 9,89). This data shows that the new GFPi 
reporter is a competent substrate for RAG activity and that the designed IVRA, either using 
H2k-RAG or CMV-RAG, provides a broader window for quantitation of RAG activity.  
We next sought to understand whether various baseline levels of recombination could 
be obtained when using the GFPi-Cons reporter along with the CMV-RAG expression 
system. We aimed at defining the assay that better allowed observing increasing or 
decreasing differences between different GFPi constructs. To that aim, we titrated down the 
amounts of CMV-RAG plasmids used along with GFPi-Cons in the cell transfection and 
proceed to determine RAG activity. Progressive 2-fold decreases in CMV-RAG plasmid 
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Figure 6. Efficiency of recombination values for 
GFPi-Cons upon CMV-RAG plasmid titration in 
IVRAs. CMV-RAG1 and CMV-RAG2 expression 
plasmids were titrated down by half from 1,4μg and 
1,6 μg (CMV-RAG) to 0,175 μg and 0,2 μg (0,0625x 
CMV-RAG), respectively; one to two independent 
experiments, each with n=3 replicates; ER = 
Efficiency of Recombination. 
Figure 7. Representative flow cytometry analysis of successive CMV-RAG GFPi IVRAs with 
decreasing titrated levels of CMV-RAG plasmid amounts. GFPi-Cons IVRA in absence of CMV-
RAG was used as a negative control (upper left); CMV-RAG1 and CMV-RAG2 expression plasmids 
were titrated down by half from 1,4μg and 1,6 μg (CMV-RAG) to 0,175 μg and 0,2 μg (0,0625x CMV-
RAG), respectively; events were gated on RFP+ (x axis) and GFP+ (y axis); the frequency of double-
positive events (ER) average and standard deviation is highlighted in bold; n=3 replicates of one 
independent experiment. 
amounts, from 1,4-1,6 g to 0,175-0,2 g, did not correlate with significant differences in ER 
or with differences proportional to the plasmid reduction (Fig.6, Fig.7).  
This observation suggested that CMV-
RAG plasmid amounts express levels of protein 
which approach functional saturation. This 
conclusion is also supported by the ER values obtained for high amounts of substrate which 
reach 91-97% for a RFP Mean Intensity of Fluorescence (MIFRFP) around 150 and 400 (data 
not shown).  
Therefore, we propose that the CMV-RAG GFPi assay cannot be used to compare 
RAG activity at least of 
consensus-like RSSs since 
non-saturating conditions can 
only be reached with very 
small amounts of CMV-RAG 
DNA which may be limiting in 
the transfection reaction. 
Overall, we have successfully 
optimized the GFPi assay 
creating a broader window of 
RAG activity measurement 
with the use of H2k-RAG and 
CMV-RAG, which may be 
useful to study cryptic RSSs. 
4.2. GFPi sensitivity to 23-RSS sequence degeneration 
We aimed at determining whether the GFPi reporter was able to provide a fine 
quantitation of RAG activity in vitro, paralleling the pJH290 system. As so, Kelsoe and 
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A B 
Figure 8. p290T and H2k-RAG GFPi 23-RSS reporters’ ERs. A. Graphical representation of 
Kelsoe and colleagues p290T-23-RSS reporters IVRA results78 B. GFPi-23-RSS reporters IVRAs 
using H2k-RAG plasmids; two to three pooled independent experiments each with n=3 replicates; 
ER = Efficiency of Recombination. 
colleagues’ RSS analysis was here reproduced by using the GFPi reporter. Six variations to 
the GFPi-Cons reporter were generated (GFPi-ConK, GFPi-spaMI, GFPi-(MI)G4, GFPi-
(MI)G14/15, GFPi-(MI)C19/20 and GFPi-spaMI-CAGnon), bearing the same 12-RSS but 
differing in the 23-RSS (as described in 78), and were further used in IVRAs for ER 
determination. 
Despite the high values of ER obtained with CMV-RAG in this work, we decided to 
use H2k-RAG to test the 23-RSSs due to the fact that some RSS sequences which were 
predicted to be highly efficient78 (eg. spaMI) would not be properly assessed in the saturating 
conditions observed previously with GFPi-Cons.  
As a first approach, the 23-RSSs were analysed with the RIC algorithm developed by 
Kelsoe et al.79; all tested 23-RSS sequences were predicted to be functional, since their 
score was ≥-60 (Table III, App.). 
When comparing the literature’s 23-RSS analysis in the p290T setup (Fig.8 A,78) to 
the H2k-RAG GFPi setup (Fig.8 B, Fig.9), we find a narrower window of ER values in the 
case of H2k-RAG GFPi, which ranged from an ER of 0,32% to 5,89%, contrasting to p290T 
which ranged from 0% to 33,3%. Nevertheless, we also observed a remarkable difference 
between standard deviations of both assays: H2k-RAG GFPi exhibited ratios 
average/standard deviation ranging from 15% to 37% while p290T ranged from 18% to 
100%. Since the data points of the literature’s experiment were not available, it was not 
possible to compare the p290T and GFPi IVRA RAG activity measurements by using 
powerful statistical testing. Thus, we took a simple though suitable statistical approach: the 
fold difference coefficient calculation between ER values of 23-RSS pT290 and GFPi 
constructs. Fold-difference values were calculated for every set of two constructs, by dividing 
the respective ER values, either in the p290T (Table IV, App.) or the H2k-RAG GFPi assay 
(Table V, App.). These were then compared between the two assays, by calculating the 
respective coefficient value for every pair of constructs (Table VI, App.). If both assays were 
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Figure 9. Representative flow cytometry analysis plots of negative control GFPi-Cons IVRA 
(upper left) and H2k-RAG 23-RSS GFPi IVRAs. GFPi-Cons IVRA in absence of CMV-RAG was 
used as a negative control (upper left); Events were gated on RFP+ (x axis) and GFP+ (y axis); the 
frequency of double-positive events (ER) average and standard deviation is highlighted in bold; n=3 
replicates of one independent experiment. 
Figure 10. CMV-RAG 23-RSS GFPi reporters’ 
ERs. GFPi-spaMI-CAGnon, GFPi-Cons and GFPi-
(MI)C19/20 23-RSS reporters IVRAs using CMV-
RAG plasmids; one to two pooled independent 
experiments each with  n=3 replicates; ER = 
Efficiency of Recombination. 
similar, Table VI. (App.) should present the same value in every cell. The coefficient values 
obtained were observed to vary in a narrow interval, from a coefficient of 0,8 to 3,1. The 
bigger differences were found in (MI)G4 and spaMI coefficients. Discarding these, the 
analysis is consistent to a general similarity between the p290T and the GFPi assays.  
 From these results, we conclude that H2k-RAG GFPi assay holds a power of 
discrimination which lies mainly on lower ER values. GFPi was able to partially reproduce the 
23-RSS ranking, correctly discriminating the ER of four constructs out of seven. These data 
show that the GFPi reporter is at least partially sensitive to RSS sequence variations allowing 
for the detection of absolute values of efficiency of recombination in a range at least equal to 
that exhibited by the analysis with p290T, therefore providing a tool to detect differences in 
RAG activity. 
The CMV-RAG GFPi system appeared 
to be ideal to study RSSs with low efficiency of 
recombination, particularly cryptic RSSs. 
Therefore, we decided to better analyze the 23-
RSS GFPi constructs which had provided the 
most extreme ER values in the H2k-RAG GFPi assay (GFPi-(MI)C19/20 and the low-
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Figure 11. Representative flow cytometry analysis plots of CMV-RAG 23-RSS GFPi IVRAs. 
GFPi-Cons IVRA in absence of CMV-RAG was used as a negative control (left); events were gated 
on RFP+ (x axis) and GFP+ (y axis); the frequency of double-positive events (ER) average and 
standard deviation is highlighted in bold; n=3 replicates of one independent experiment. 
efficiency GFPi-spaMI-CAGnon reporters) by using the CMV-RAG GFPi system and 
compare them to the consensus construct (GFPi-Cons) used initially in this IVRA setup. 
Herein, the window of ER values was much broader, as expected (Table VII in App., 
Fig.10, Fig.11). The value observed for GFPi-Cons remained as the highest value (ER = 
54,2 ± 1), since GFPi-(MI)C19/20 did not exhibit higher value in this assay (ER = 58,58 ± 
0,63), contrarily to what was observed with H2k-RAG. This consolidates the previous 
observation that in these conditions the assay is not discriminatory for RSSs with a high 
efficiency. Interestingly, the ER of GFPi-spaMI-CAGnon (ER = 14,49% ± 0,52) increased 28-
fold when compared to the H2k-RAG ER value (ER = 0,51 ± 0,19) and the approximate 4-
fold increase in ER from GFPi-spaMI-CAGnon to GFPi-Cons observed in the H2k assay was 
maintained in the CMV analysis. These data indicate that the CMV-RAG assay is most 
suitable to study cRSSs with predicted residual RAG activity or previously undetected ER. 
With these results, we concluded that the GFPi assay bears the ability to measure 
RAG activity on a broad range of ER levels, since H2k-RAG is suitable for highly efficient 
RSS ER measurement whereas CMV-RAG is able to detect low efficiencies of 
recombination, therefore providing a versatile tool for further application. 
4.3. Assessment of RAG-mediated cRSS functionality in vitro 
The question underlying the relationship between RAG and its effect on oncogenesis 
by cRSS targeting has been addressed for long (referred in 1.3.2.). So far, the molecular 
studies undertaken have required laborious and time-demanding work. At this stage, due to 
the advantages of the GFPi reporter, we decided to validate this tool for RAG activity 
detection in cRSSs. 
For the validation of the CMV-RAG cRSS-GFPi assay, we have selected a set of 
described 12-cRSSs and two V(D)J loci 12-RSSs: Jβ2-2, herein named as Jβ, and 
VH1/87(181), or VH, selected from different AR loci (TCRβ and IgH, respectively). Both were 
previously shown to exhibit barely detectable functionality levels63, 83, 84, thus reflecting low 
usage of these segments by RAG83, 85.  12-cRSSs were selected from Lmo2 and SCL genes 
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Figure 12. Efficiency of recombination obtained for 
each GFPi-RSS/cRSS reporter. GFPi-Cons ER value is 
used as a control; one to two pooled independent 
experiments each with n=3 replicates; ER = Efficiency of 
Recombination.
Figure 13. Representative 
flow cytometry analysis 
plots of CMV-RAG 12-
RSS/cRSS-GFPi IVRAs. 
GFPi-Cons IVRA in absence 
of CMV-RAG was used as a 
negative control (left); events 
were gated on RFP+ (x axis) 
and GFP+ (y axis); the 
frequency of double-positive 
events (ER) average and 
standard deviation is 
highlighted in bold; n=3 
replicates of one independent 
experiment. 
(known to be involved in T-ALL onset) the first having been described as functionally 
efficient85 and the second considered undetectable85 (as shown in Table VIII, App.).  
As a preliminary approach, we have addressed RSS/cRSS functionalities by running 
the RIC score algorithm for all the referred 
sequences and found that all sequences 
exhibited RIC scores lower than the functionality 
threshold, with the exception of Jβ2-2 which 
presented a RIC score of -37,8 (Table VIII, App.). 
Subsequently, four GFPi-reporters were generated in a similar manner to the GFPi 
23-RSS constructs (referred in 4.2.), all containing the same 23-RSS sequence (Cons) but 
differing in the 12-RSS:  GFPi-VH, GFPi-Jβ, GFPi-Lmo2 and GFPi-SCL. For each reporter, 
the ER was determined by IVRA using CMV-RAG expression plasmids in order to 
successfully detect residual RAG activity (Table VIII, App.). 
Concerning the comparison between ERs of each GFPi-RSS/cRSS reporter, all 
reporters presented lower ERs than the reference ER value of GFPi-Cons (Fig.12, Fig.13). 
In these assays, GFPi-Lmo2 was shown to be much more functional (exhibiting an ER of 
14,67% ± 0,16) than the two V(D)J loci RSS reporters (ER = 6,77% ± 0,39 for GFPi-VH and 
ER = 4,41% ± 0,13 for GFPi-Jβ). GFPi-SCL presented residual RAG activity levels (with a 
low though detectable ER of 0,28% ± 0,1).  
Hence, the CMV-RAG GFPi IVRA assay was successfully established as a cRSS 
assay, which allowed for 
the successful detection 
of low levels of RAG 
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Figure 15. Representative flow cytometry analysis plots of negative control GFPi-Cons IVRA 
(left), and CMV-RAG GFPi-Jβ (middle) and GFPi-PTEN (right) cRSS IVRAs. Events were gated on 
RFP+ (x axis) and GFP+ (y axis); the frequency of double-positive events (ER) average and standard 
deviation is highlighted in bold; n=3 replicates of one independent experiment. 
Figure 14. Efficiency of recombination obtained for 
GFPi-PTEN cRSS reporter. GFPi-Jβ ER value is used as 
a control; one independent experiment containing n=3 
replicates.
activity not only in low-efficient RSSs but also in a cRSS with previously undetectable ER 
levels. 
4.4. Assessment of RAG-mediated PTEN cRSS functionality in vitro 
PTEN (phosphatase and tensin homologue deleted on chromosome 10) gene 
encodes for a phosphatase that is part of the phosphatidylinositol-3 kinase (PI3K) 
/PTEN/protein kinase B (Akt) pathway which plays an important role on cell metabolism, 
proliferation, cell cycle progression and survival86. 
Mutations in the PTEN gene have been 
associated with brain tumours and more recently 
to T-ALL generation87. Recently, this gene was 
found mutated in a T-ALL leukaemia patient 
(unpublished data, Barata et al.). Sequencing 
analysis has revealed a novel mutation located 
within PTEN’s first exon, exhibiting a deletion of a 12-nucleotide fragment (which disrupted 
the ATG start codon) and an addition of 14 nucleotides in a proximate region. We have used 
the RIC score algorithm to screen for cRSSs in this particular region of the PTEN gene. A 12-
cRSS sequence was predicted to exist adjacently to the referred mutation site, bearing a RIC 
score of -45,5 (near the -40 threshold of functionality). In an attempt to understand a possible 
relation between this cRSS and the referred mutation, we assessed its functionality upon 
RAG activity by generating GFPi-PTEN and testing this reporter in the CMV-RAG cRSS 
GFPi assay, along with the previously tested low efficiency Jβ cRSS, as a control. 
GFPi-PTEN exhibited 
similar ER values to 
GFPi-Jβ (confirmed by 
a t-test comparison, 
p>0,05), exhibiting an 
ER of 4,39% ± 0,23 
(Fig.14, Fig.15). 
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4.5. Endogenous RAG activity detection in human haematopoietic tumour cell lines 
Leukaemias, representing a large proportion of haematological malignancies, are 
described as having disrupted haematopoietic differentiation88. Acute leukaemias are 
characterized by a haematopoietic developmental arrest of immature cells, accompanied by 
a boost of cell proliferation, whereas chronic leukaemias are originated from more mature 
cell stages and develop at a much slower rate. Although leukaemias are classified according 
to their lymphoid or myeloid origin, in some cases, the leukaemic cell type may carry 
biphenotipic markers72, which may suggest that both lineages are not so well defined. 
Considering the promiscuity of RAG expression58 and activity19, together with the genetic 
plasticity of transformed cells in the context of haematopoiesis, we hypothesised a role for 
RAG in the origin and/or progression of leukaemic genomic instability, either inside or 
beyond the lymphoid compartment. 
As an initial approach, we performed a systematic screen for endogenous RAG 
activity in lymphoid and myeloid human tumour cell lines, as it had previously been assessed 
with classical replicative extrachromosomal reporters89, 90. However, we aimed at creating a 
more physiological setup by using the GFPi-Cons retroviral-based reporter as an integrated 
and low copy number substrate. For that, pseudo-retroviruses of control (MSCV-mRFP) and 
GFPi-Cons reporters were produced and used to infect a collection of myeloid and lymphoid 
human tumour cell lines, kindly provided by the Unidade de Biologia do Cancro, Instituto de 
Medicina Molecular and Instituto Português de Oncologia. HL-60 and K-562 myeloid cell 
lines were originally collected from a leukaemic patient with APL and from CML (Chronic 
Myelogenous Leukaemia) in blast crisis (i.e., the terminal phase of CML), respectively. SUP-
T1 and Jurkat lymphoid cell lines were originated from T-ALL whereas Reh and NALM-6 
were from B-ALL. The assessment of RAG activity was performed in the reporter-infected 
cells by flow cytometry analysis, in a similar manner to the above tasks of this work.  
The optimum conditions for cell analysis were found at two weeks post-infection (Fig. 
16). The dynamics of RAG activity in a time-dependent manner could not be assessed, since 
the rate of infected cells was not stable throughout time. Regarding the ER values obtained 
with the integrative GFPi-Cons reporter (Table IX, App.) and the respective flow cytometry 
profiles (Fig.16), all lymphoid cell lines presented RAG activity, whereas HL-60 and K-562 
myeloid cell lines seemed devoided of it (the ER of HL-60 was 0,05% and K-562 was 0%). 
Both B-ALL cell lines displayed a clear double-positive population: NALM-6 had an ER of 
1,19% and Reh presented the highest ER of all tested cell lines (ER = 13,61%). Concerning 
T-ALL cell lines, both presented a very scattered double-positive population, different from 
the profile found in B-ALL. Jurkat’s ER value of 1,11% was quite similar to the one of NALM-
6 and SUP-T1 presented very low values of endogenous RAG activity (ER = 0,24%). 
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Figure 16. Flow cytometry plots of human tumour cell lines (HL-60, K-562, SUP-T1, Jurkat, 
NALM-6 and Reh) infected with control (MSCV-mRFP) or GFPi-Cons retroviral-based 
reporters at three weeks post-infection. All acquisitions are on RFP-positive gated populations, 
where the GFP-positive events are indicated in frequency on the upper right corner of each plot. This 
frequency represents the respective ER of a single experiment. The final ER of each cell line is 
calculated by the following manner: ER (cell line) = ER (GFPi-Cons) – ER (MSCV-mRFP). 
This work showed that the GFPi retroviral-based system is efficient in detecting 
endogenous RAG activity. Moreover, it also demonstrated that GFPi is sensitive to different 
RAG activity levels (as previously observed in vitro in this work). 
5. DISCUSSION 
5.1. Optimization of the GFPi IVRA 
In this work, we were able to establish the GFPi reporter as a highly efficient tool for 
RAG activity measurement, coupled with a simpler and straightforward method of readout. 
We were able to optimize this assay, making it highly efficient and obtaining ER values 
reaching 60%, with a simple IVRA protocol, requiring transfection and dual-fluorescence flow 
cytometry analysis. 
 We have found that GFPi is correctly built, successfully presenting a readout of RAG 
activity. Flanking sequences present on the MSCV vector were found not to be limiting RAG 
efficiency of recombination since an increase in RAG expression, provided by the CMV-RAG 
expression plasmids, produced a parallel increment on the ER value. Furthermore, we 
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observed H2k-driven expression was indeed limiting the ER since accounting for the 
unexpected low values of ER first obtained with the GFPi dual fluorescence readout.  
CMV-RAG levels of expression in the established GFPi-Cons assay produced a 
substantially higher ER than that measured with pJH290 under endogenous RAG 
expression78. More strikingly, the MSCV-GFPi readout detected a much higher ER than 
pJH290 system when transfecting similar amounts of CMV-RAG constructs40. Furthermore, 
we concluded that RAG protein saturation levels are achieved for higher numbers of reporter 
molecules (MIFRFP > 150), as seen when analyzing CMV-RAG GFPi-Cons flow cytometry 
plots, which present an ER of almost 100% in the highest peak of RFP intensity. These 
analyses have also shown that saturation levels are achieved in a RFP intensity of 102 which 
indicate an increasing probability of RAG finding reporter molecules and that the assay is 
limited in RAG activity for the low copy number transfectants. Therefore, we hypothesize that 
dispersed substrates are more difficult to be targeted by RAG in this case. 
It would be interesting to determine the number of reporter plasmids within a cell with 
a given RFP brightness (namely, by qPCR). With that, it would be possible to determine the 
number of recombined plasmids within a cell, conferring another type of sensitivity to the ER 
values (molecule-level instead of cell-level) and better compare the results to those of 
molecule-determination assays21. We found an indication of this value by calculating the 
mean intensity of GFP fluorescence (MIFGFP), proportional to the average number of 
recombined reporters per cell, times the percentage of GFP+ cells, for a population with a 
given RFP intensity. 
A broader window of RAG activity measurement has been achieved by increasing 
RAG expression levels in the IVRA. Therefore, we conclude that the GFPi assay is suitable 
for conditions when expecting higher ERs (by using H2k-RAG) and lower ERs (by using 
CMV-RAG). This optimization allowed for further validation and application of the GFPi 
reporter in this work. 
5.2. GFPi sensitivity to 23-RSS sequence degeneration 
Through the use of the GFPi reporter system, we have successfully proven its 
general sensitivity to differences in 23-RSS spacer sequence composition and consequently 
to quantification of RAG activity in vitro.  
We have found that the results obtained follow a general trend to reproduce Kelsoe 
and colleagues 23-RSS analysis by using the GFPi reporter system, obtaining a gradient of 
ER values similar to that of the p290T 23-RSS reporters78, with the exception of GFPi-spaMI 
and GFPi-(MI)G4. We have confirmed GFPi-spaMI and GFPi-(MI)G4 sequence composition 
by sequencing analysis. We were particularly surprised by spaMI RIC score and ER results. 
spaMI, published as the best 23-RSS spacer, should have reflected the best construct 
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provided by Kelsoe’s algorithm (i.e. the highest RIC score). Moreover, since all other 
sequences are derived from it to the consensus spacer (Cons), its ER was believed to be the 
highest.  
We hypothesize that these differences are due to the type of measurement: GFPi 
assay differs from Kelsoe and colleagues’ in the sense that we have used cell lines devoided 
of RAG expression for further lipofectamine-mediated transfection with RAG and reporter 
plasmids (and not a pre-B cell line with endogenous RAG expression, transfected by 
electroporation with the reporter) and measured RAG activity at the cell level (and not at the 
molecule level). To support our findings, we used an indication of the number of recombined 
reporter molecules per cell, MIFGFP, in GFPi-spaMI and GFPi-(MI)C19/20 and compared both 
MIFGFP values. It is usually considered in flow cytometry analysis that MIF depicts (or is 
proportional) to the number of existing fluorescent molecules. As fluorescence is a function of 
the number of gene copies being expressed, we reasoned that the MIFGFP should provide a 
measure of the number of recombined events (i.e. number of copies in frame) occurring in 
each analysed cell. Our findings still stand even when performing the MIFGFP analysis (data 
not shown).  
To further confirm this difference we have specifically tested GFPi-spaMI in IVRAs 
using CMV-RAG expression plasmids to find that GFPi-spaMI still originates a lower ER than 
that of GFPi-Cons or GFPi-(MI)C19/20 (data not shown).  
Regarding the RIC score algorithm, Kelsoe and colleagues state that the RIC score 
algorithm provides a quantitative value of function. Our analysis of ER and RIC score does 
not generally corroborate this statement for all constructs tested. Strikingly, the spaMI-
CAGnon 23-RSS sequence, containing the CAG-motif nonamer which confers low RAG 
efficiency78 to the otherwise spaMI sequence, presents the highest RIC score. This finding 
demonstrates the algorithm’s inability to measure the functional inefficiency of the nonamer 
coupled with the efficient spaMI heptamer and spacer. The opinions are controversial 
regarding the informative power of the RIC score. While Lieber et al. support its quantitative 
sensitivity83, others have shown, like us, that the algorithm is only powerful qualitatively91. 
In our results, we have observed a narrower window of ER values than in Kelsoe and 
colleagues work, resulting in a less discriminative assay. However, the replicates increased 
the reliability of the GFPi assay since its standard deviation values are much narrower than 
those of p290T, revealing its statistical robustness.  
Another factor that might as well have influenced the p290T and GFPi different results 
is the reporter sequence composition flanking RSS. Roth et al. has made an extensive study 
on the impact of RSS sequence neighbourhoods on ER. We found that GFPi bears 
5’GG/3’CC motifs flanking the 23-RSS sequence and those were predicted to be 5% less 
functional than the p290T 5’CT/3’AG motifs92. Moreover, we speculate that different 
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neighbourhoods may also influence RSSs in a specific manner, namely by having a 
synergistic effect in combination with specific spacers, although we have no such evidence. 
Finally, we expect these experiments to establish our reporter system as an 
alternative tool to the classic pJH290 system. It was certainly demonstrated that the GFPi 
reporter structure is able to provide an excellent quantitative readout. Therefore, an efficient 
and sensitive RAG activity reporter system was generated, by relying on a single-step 
analysis, eliminating the expensive, time-consuming and technically challenging procedures 
inherent to the pJH290 reporter. 
5.3. Assessment of RAG-mediated cRSS functionality in vitro 
We have successfully applied the CMV-RAG GFPi assay as a more suitable 
approach for assessing cRSS functionality in terms of RAG activity. We have found that all 
tested 12-cRSSs are targeted by RAG and are engaged in aberrant recombination 
rearrangements, though with varying frequencies. 
The SCL (stem cell leukaemia) gene, (also known as TAL-1 - T-cell acute 
lymphoblastic leukaemia-1 - or TCL-5) is located on chromosome 1 in the human genome 
and encodes a transcription factor which plays a role in blood vessel formation, endothelial 
development and T-cell development during haematopoiesis93. Aberrant SCL 
rearrangements are the most common defects associated with T-ALL, being described in 
60% of T-ALL patients94. The most frequent, affecting 25% of T-ALL patients, is the SCL-SIL 
submicroscopic deletion, which is an 82kb interstitial deletion that replaces regulatory SCL 
5V sequences by those of an upstream gene, known as SCL-interrupting locus (SIL)93. SCL-
SIL mutation was described as being induced by RAG illegitimate activity. We have studied 
the 12-cRSS found to exist within the rearranged region. 
Lmo2 (LIM domain only-2) gene is located on chromosome 11 and encodes for a 
transcriptional cofactor that was shown to be involved in vascular endothelial remodelling 
and hematopoietic development. After differentiation of haematopoietic stem cells, Lmo2 is 
downregulated in T-lymphocytes95. However, RAG illegitimate activity was shown to induce 
deletion or translocation causing aberrant rearrangements of this gene, ectopic induction of 
Lmo2 expression and T-ALL onset85. 
When comparing ER values described in the literature to those obtained with GFPi, 
SCL presented a lower ER than Lmo2 as in Lieber et al. but VH1/87(181) and Jβ2-2 reversed 
their ER ranking, contrasting with Kelsoe et al. observations84, 85. Nevertheless, it is important 
to bear in mind that VH1/87(181) and Jβ2-2 were previously tested through the use of a 
murine cell line, whereas Lmo2 and SCL in a Reh human pre-B tumour cell line, both already 
bearing endogenous RAG expression. 
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Regarding the comparison of RIC score and RSS/cRSS functionality, we found no 
quantitative relation between the two. All tested sequences were classified as non-functional 
by the RIC score, with the exception of the control Cons and the Jβ2-2 V(D)J loci RSSs. 
However, in vitro, GFPi-Jβ presented a lower ER than the presumably non-functional VH. 
Therefore, in the case of cRSS characterization, the in vitro approach assay appears to more 
accurately predict cRSS functionality than the in silico approach. 
Surprisingly, two out of the three tested cRSSs (Lmo2 and PTEN) presented similar 
or higher ER values than the tested V(D)J loci RSSs. We hypothesize that regulatory 
mechanisms acting upstream of RAG targeting19, such as chromatin regulation, may be 
preventing these particular cRSSs from being targeted in vivo. Indeed, we observed a unique 
pattern of recombination frequencies along the RFP gradient (i.e increasing number of 
reporters) for these cRSSs: for the low copy number of reporter, both Lmo2 and PTEN 
presented ER values higher than those of Cons; moreover, the proportional increase in ER 
with the increasing reporter copy number observed in Cons was not observed for these 
cRSSs, which kept the ER value approximately constant. This suggests that Lmo2 and 
PTEN cRSSs, without further regulation, have higher probability of recruiting RAG yet low 
DSB and/or rearrangement capabilities. This further implies that GFPi assay may provide 
additional, unforeseen, information about the dynamics of RAG/RSS recombination process.   
Additionally, GFPi-SCL presented a lower ER than GFPi-Lmo2, in spite of SCL-SIL 
deletion being more or equally frequent than Lmo2 translocation in T-ALL patients. In this 
case, we propose a regulatory mechanism having an effect on the incidence of the mutation 
(in a given cell population), i.e. that the 1p32 SCL/SIL deletional mutation may provide a 
cellular or populational selective advantage, when compared to the Lmo2 translocation. It 
would be interesting to explore the contribution of the different mutated regions to cell 
survival and cell proliferation. 
This tool may provide a better understanding of RAG’s illegitimate activity, for 
example by assessing the functionality of other sequences related or still not related to 
RAG’s illegitimate activity (such as the remaining sequences recruited for chromosomal 
aberrations mentioned in 1.3.2.). The GFPi reporter system could also be used for testing 
coupled pairs of RSSs/cRSSs, mimicking a condition similar to a pre-translocation setup, as 
has been previously done with a few sequence pairs in reporters requiring laborious 
procedures68. 
5.4. Assessment of RAG-mediated PTEN cRSS functionality in vitro 
Our results show for the first time that the PTEN tumour suppressor gene is targeted 
by RAG in vitro. We demonstrated that the 12-cRSS adjacent to the start codon of PTEN’s 
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first exon efficiently engages in RAG-mediated recombination in vitro and that this 
phenomenon correlates with a novel mutation found at this site in a T-ALL patient.  
This particular cRSS presented a high ER when tested with the GFPi reporter: while 
GFPi-SCL presented a 52-fold lower ER than Lmo2, GFPi-PTEN was only 3-fold lower. 
Moreover, PTEN ER value was similar to those of VH and Jβ V(D)J loci RSSs.  
There is the indication of a relation between the mutation found and the occurrence of 
a RAG-mediated illegitimate event. When performing in vivo mutational analysis of the T-ALL 
patient, this novel deletional mutation, which completely abolished PTEN expression, did not 
display all the signatures characteristic of a RAG-mediated rearrangement, such as the 
strand donation signature for hairpin processing. However, we find nucleotide loss and 
adjacent addition of nucleotides in a potential RAG-induced breakage site and an intact 
signal end region adjacent to a cRSS that we found that is in fact highly functional. We 
hypothesize that this region was processed by exonuclease activity followed by nucleotide-
addition compatible with TdT activity.  
Although we have found that the cRSS present in the first exon of the PTEN gene 
showed a high efficiency of recombination in vitro, this particular exon seems to be rarely 
targeted for mutation. There is now increasing evidence for exon 7 being the preferencial 
target for mutation with several mutations from different T-ALL patients already described96. It 
has been hypothesized that the mutational hotspot of exon 7 may relate to RAG activity. 
In summary, the cRSS present within the first exon of the PTEN gene was tested for 
the first time with the use of the GFPi reporter and found to be a substrate as functional as a 
V(D)J loci RSS for RAG activity. This result thus indicates that PTEN cRSS and V(D)J loci 
RSS sequences, although similar in functionality, are clearly under different regulatory 
processes. 
5.5. Endogenous RAG activity detection in human haematopoietic tumour cell lines 
We have found that GFPi retroviral-based reporter system successfully functioned as 
an integrative low copy number substrate, being a more physiologic approach of RAG activity 
measurement in human lymphoid tumour cell lines.  
We predicted that GFPi copy number could not exceed four copies per cell [since we 
established a viral multiplicity of infection (MOI) of four and observed an efficiency of 
infection of approximately 50%]. When comparing our results to Lieber et al., we find that 
integrated GFPi displays comparable or higher ER values to those obtained with pJH290-like 
extrachromosomal substrate89, 90. Both integrated GFPi and pJH290-like reporters indicate 
that Reh bears the highest RAG activity and myeloid cell lines as having the lowest. 
However, NALM-6 and SUP-T1 presented differing results: integrated GFPi displayed similar 
ER values for both cell lines whereas Lieber et al. states that NALM-6 presents a 20-fold 
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higher ER than SUP-T1. Myeloid cell lines were found to be devoided of RAG activity, as 
expected for a cell line of myeloid origin. Nevertheless, the few observed GFP+RFP+ double-
positive events in K-562 GFPi-Cons flow cytometry analysis should be taken into account 
when performing a time-based assessment of RAG activity, since we could be witnessing 
residual RAG activity that may well become enriched throughout time.  
Due to the limited time available for the execution of this task and to its exploratory 
nature, there were no replicates/independent experiments done in this study. Further work 
should be done to replicate the infections and perform independent analysis not only to 
validate the results obtained but also to establish stable infections and analyse alterations in 
recombination events throughout time. 
 
6. Concluding remarks 
 We have successfully developed a simple RAG activity measurement tool, the GFPi 
reporter. This construct allows for transient and stable RAG activity assessment, either by in 
vitro recombination assays or by retroviral integration, gathering an efficient method of 
readout, provided by dual-fluorescence flow cytometry analysis. The GFPi IVRA was 
successfully optimized for a broader window of RAG activity measurement and for a 
functional analysis of cRSSs. We were able to apply this last technique to assess the 
functionality of a previously undescribed cRSS within the PTEN gene, which correlated with 
a novel mutation found in a T-ALL patient. This sequence is indeed targeted by RAG, 
presenting greater efficiency of recombination (ER) than other cRSSs known to be involved 
in leukaemogenesis and also presenting similar ER values to two tested V(D)J loci RSSs. 
With the retroviral-based form of GFPi, we were also able to study RAG activity in human 
leukaemic tumour cell lines with endogenous RAG expression. In this case, we have 
mimicked a more physiological RAG activity measurement, since we used the integrated 
form of GFPi in the cell genome in low-copy number. We detected RAG activity in cell lines 
of lymphoid origin, ranging in ER values in a cell-type specific manner, but not of myeloid 
origin. Overall, we conclude that the GFPi reporter system satisfies all the conditions for 
being considered as a suitable tool for RAG activity measurement, coupling a non-laborious 
assay with a simple readout method. We foresee a number of important applications of this 
polyvalent tool, ranging from biochemical studies, haematopoiesis and cancer biology 
research to biomedical applications such as diagnosis. 
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Table I. List of PCR products and respective reverse primers, 23-RSS. 
Table II. List of PCR products and respective reverse primers, 12-RSS. 
Table III. List of 23-RSS reporters and respective RIC score, average efficiency of 
recombination (ER) and standard deviation (SD) in pT29078 and H2k-RAG GFPi IVRAs (with 
two to three independent experiments, each with n=3 replicates).
TABLES 
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Table VIII. List of RSS (Cons, VH and Jβ) and cRSS (Lmo2, SCL) reporters, respective 
efficiency of recombination (ER) and standard deviation (SD) in literature reporter assays and 
CMV-RAG GFPi IVRAs (one to two independent experiments with n=3 replicates each). 
 
*1 Kelsoe et al., 2004 *2 Kelsoe e tal, 2007 *3 Lieber e tal, 2001 
Table VII. List of 23-RSS reporters, respective efficiency of recombination (ER) and standard 
deviation (SD) in CMV-RAG GFPi IVRAs (one to two independent experiments with n=3 
replicates each). 
 
 
 
 
 
 
 
 
Table IV. Fold difference coefficients between ER values of the p290T 
Table V. Fold difference coefficients between ER values of the H2k-RAG GFPi 
Table VI. Coefficient of fold difference between ER values of p290T and H2k-RAG GFPi . 
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Table IX. List of human haematopoietic cell lines and respective efficiency of recombination 
(ER) measured either in the literature (pGG49) or with the retroviral-based GFPi-Cons 
reporter. 
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Figure II. Schematic representation 
exemplifying an environmental regulatory 
mechanism affecting V(D)J recombination. 
In Desiderio et al., 1999. 
Figure I. Phylogenic representation of 
immune function characteristics, 
mechanisms of genetic organization and 
diversity generation events in selected 
species. In Dishaw et al, 2005. 
FIGURES 
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Figure IV. Immunoblot of H2k and CMV-RAG proteins. 293T cells were transfected either with 
mock (-), H2k-RAG1, CMV-RAG1, H2k-RAG2 or CMV-RAG2 plasmids and the respective protein 
extracts were further used for Immunoblot analysis. H2k-RAG1, CMV-RAG1 and α-tubulin (internal 
control) were detected by using A. anti-RAG1 antibody in a concentration of 1:500 and anti-α-
tubulin in 1:500 and B. anti-RAG1 1:100 and anti-α-tubulin 1:1000. H2k-RAG2, CMV-RAG2 and β-
actin (internal control) were detected by using C. anti-RAG2 antibody in a concentration of 1:500 
and anti-β-actin 1:2000 and D. anti-RAG2 1:50 and anti-β-actin 1:1000.
Figure III. Expected GFPi-Cons PCR product sequence (5’ to 3’). The inverted complementary 
sequence of the Kozak (in light-green) fused to the GFP (green) are flanked at 5’ by a 12- and at 3’ 
by a 23-RSS. RSSs are composed by a heptamer (in red), a spacer (in black) and a nonamer (in 
blue). 5’ XhoI and 3’ SmaI restriction sites are indicated in black bold. Primer regions are underlined. 
 
 
 
 
 
 
 
 
